| [1]Vilma VS, de Carvalho JF, de Moraes JC, et al.Autoantibodies in patients with psoriatic arthritis on anti-TNFa therapy.Rev Bras Rheumatol,2010,50(3):225-234[2]Antoni CE, Kavanaugh A, Kirkham B, et al.Sustained Benefits of Infliximab Therapy for Dermatologic and Articular Manifestations of Psoriatic Arthritis.Arthritis Rheum,2005,52(4):1227-1236[3]Antoni CE, Kavanaugh A, Van der Heijde D, et al.Two-Year Efficacy and Safety of Infliximab Treatment in Patients with Active Psoriatic Arthritis:Findings of the Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT).J Rheumatology,2008,35(5):869-876[4]Smolen JS, Emery P.Infliximab: 12 2011s of experience.Arthritis Res Ther,2011,13Suppl 1:1-18[5]Voulgari PV, Venetsanopoulou AI, Exarchou SA, et al.Sustained Clinical Response and High In?iximab Survival in Psoriatic Arthritis Patients: A 3-2008 Long-Term Study.Semin Arthritis Rheum,2008,37(5):293-298[6]Di Renzo L, Saraceno R, Schipani C, et al.Why 3 mg?kg instead of 5 mg?kg of in?iximab should work in psoriatic arthritis.J Dermatology,2009,36(12):666-668[7]Alstergren P, Larsson PT, Kopp S, et al.Successful treatment with multiple intra-articular injections of infliximab in a patient with psoriatic arthritis.Scand J Rheumatol,2008,37(2):155-157[8]Conti F, Ceccarelli F, Priori R, et al.Intra-articular infliximab in patients with rheumatoid arthritis and psoriatic arthritis with monoarthritis resistant to local glucocorticoids.Clinical efficacy extended to patients on systemic anti-tumour necrosis factorα, Ann Rheum Dis,2008,67(12):1787-1790[9]Antoni C, Krueger GG, de Vlam K, et al.Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial.Ann Rheum Dis,2005,64(8):1150-1157[10]Saad AA, Ashcroft DM, Watson KD, et al.Improvements in Quality of Life and Functional Status in Patients With Psoriatic Arthritis Receiving Anti–Tumor Necrosis Factor.Therapies Arthritis Care Res,2010,62(3):345-353[11]Torii H, Nakagawa H.Infliximab monotherapy in Japanese patients with moderate-to-severe plaque psoriasis and psoriatic arthritis.A randomized, double-blind, placebo-controlled multicenter trial. Journal of Dermatol Sci,2010,59(1):40-49[12]Xie X, Chen JW, Li F, et al.infliximab treatment in two Chinese patients with psoriatic arthritis.J Zhejiang Univ Sci B,2010,11(10):779-782[13]Vesel T, Luzar B, Calonje E.Syringotropic hypersensitivity reaction associated with infliximab and leflunomide combination therapy in a child with psoriatic arthritis.J Cutan Pathol,2009,36(9):991-994[14]Baranauskaite A, Raffayová H, Kungurov NV, et al.In?iximab plus methotrexate is superior to methotrexate alone in the treatment of psoriatic arthritis in methotrexate-naive patients: the RESPOND study.Ann Rheum Dis,2012,71(4):541-548[15]Bojke L, Epstein D, Craig D.Modelling the cost-effectiveness of biologic treatments for psoriatic arthritis.Rheumatology,2011,50(4):39-47[16]Saad AA, Ashcroft DM, Watson KD, et al.Persistence with anti-tumour necrosis factor therapies in patients with psoriatic arthritis: observational study from the British Society of Rheumatology Biologics Register.Arthritis Res Ther,2009,11(2):1-9[17]Torii H, Nakagawa H.Long-term study of infliximab in Japanese patients with plaque psoriasis, psoriatic arthritis, pustular psoriasis and psoriatic erythroderma.J Dermatol,2011,38(4):321-334 |
